Immunohistochemistry of Pituitary Adenomas

  • B. K. Kleinschmidt-DeMasters
Part of the Contemporary Endocrinology book series (COE, volume 3)

Abstract

The use of immunohistochemical staining has had a considerable impact on general surgical pathology, where it serves to clarify the diagnosis on confusing cases. In contrast, immunohistochemistry for pituitary adenomas is seldom necessary to make the diagnosis but has, along with transmission electron microscopy, served as the backbone for a modern classification system of adenoma subtypes. The surety with which most pituitary adenomas are diagnosed preoperatively via their clinical presentations, serum hormone values, and/or radio-graphic studies of the sellar region (usually magnetic resonance imaging) often make the role of the pathologist or neuropathologist who sees pituitary adenomas under the microscope one of confirmation (1). Only occasionally do other sellar masses mimic pituitary adenomas preoperatively, and then the light microscopic appearance, either at the time of frozen or permanent histological section, is usually all that is necessary to identify the type of tumor. Rarely is it necessary to employ immunohistochemistry for the differential diagnosis of sellar region masses.

Keywords

Dopamine Shrinkage Myeloma Prolactin Meningioma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Miller DC. Histopathologic evaluation of pituitary tumors: Help for the clinician in diagnosis and management of pituitary adenomas. In: Cooper PR, ed. Contemporary Diagnosis and Management of Pituitary Adenomas. American Association of Neurological Surgeons Publication, Park Ridge, IL, 1991, pp. 37–52.Google Scholar
  2. 2.
    Burger PC, Scheithauer BW, Vogel FS. Region of the Sella Turcica. In: Surgical Pathology of the Nervous System and its Coverings. 3rd ed., Churchill Livingstone, New York, 1981, pp. 503–568.Google Scholar
  3. 3.
    Kovacs K, Horvath E. Tumors of the pituitary gland. Atlas of Tumor Pathology. Second Series, Armed Forces Institute of Pathology, Washington, DC, 1986, pp. 90, 128.Google Scholar
  4. 4.
    Rush S, Newall J. Concepts in integrating radiotherapy into pituitary tumor management. In: Cooper PR, ed. Contemporary Diagnosis and Management of Pituitary Adenomas. American Association of Neurological Surgeons, Park Ridge, IL, 1991, pp. 151–164.Google Scholar
  5. 5.
    Boenisch T. Bone Immunohistochemistry. In: Naish SJ, ed. Handbook of Immunohistochemical Staining Methods. Dako Corporation, Carpinteria, CA, 1989, pp. 7,8.Google Scholar
  6. 6.
    Shi S-R, Key ME, Kalra, KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991; 39:741–748.PubMedCrossRefGoogle Scholar
  7. 7.
    Rosai J. Special techniques in surgical pathology. In: Rosai J, ed. Ackerman’s Surgical Pathology. Mosby, St. Louis, MO, 1989, pp. 31–51.Google Scholar
  8. 8.
    Stefaneau L, Kovacs K. Light microscopic special stains and immunochemistry. In: Lloyd RV, ed. The Diagnostic of Pituitary Adenomas in Surgical Pathology of the Pituitary Gland. Saunders, Philadelphia, PA, 1993, pp. 34–51.Google Scholar
  9. 9.
    Pahlman S, Esscher T, Nitsson K. Expression of “subunit of enolase”, neuron-specific enolase in human non-neuroendocrine tumors and derived cell lines. Lab Invest 1986; 54:554–560,PubMedGoogle Scholar
  10. 10.
    Juneau P, Schoene WC, Black P. Malignant tumors in the pituitary gland. Arch Neurol 1992; 49:555–558.PubMedGoogle Scholar
  11. 11.
    Kleinschmidt-DeMasters BK, Winston KR, Rubinstein D, Samuels MH. Ectopic pituitary adenoma of the third ventricle. Case report. J Neurosurg 1990; 72:139–142.PubMedCrossRefGoogle Scholar
  12. 11a.
    Burger PC, Scheithauer BW, Vogel FS. Surgical Pathology of the Nervous System And Its Coverings. Churchill Livingstone, New York, 1991.Google Scholar
  13. 12.
    Asa SL, Gerrie SM, Singer W, Horvath E, Kovacs K, Smyth HS. Gonadotrophin secretion in vitro by human pituitary null cell adenomas and oncocytomas. J Clin Endocrinol Metab 1986; 62:1011–1019.PubMedCrossRefGoogle Scholar
  14. 13.
    Furahata S, Kameya T, Tsuruta T, Naritaka TH, Toya S. Colocalization of growth hormone (GH) and glycoprotein subunit alpha in GH-producing pituitary adenomas in acromegalic patients. Acta Neuropathol 1994;87:568–571.CrossRefGoogle Scholar
  15. 14.
    Charpin C, Hassoun J, Oliver C, Jaquet P, Argemi B, Grisoli F, Toga M. Immunohistochemical and immu-noelectron-microscopic study of pituitary adenomas associated with Cushing’s disease. A report of 13 cases. Am J Pathol 1982; 109:1–7.PubMedGoogle Scholar
  16. 15.
    Demura R, Jibiki K, Kubo O, Odagiri E, Demura H, Kitamura K, Shizume K. The significance of alpha subunit as a tumor marker for gonadotropin producing pituitary adenomas. J Clin Endocrinol Metab 1986; 63:564–569.PubMedCrossRefGoogle Scholar
  17. 16.
    Kovalic JJ, Mazoujian G, McKeel DW, Fineberg BB, Grigsby PW Immunohistochemistry as a predictor of clinical outcome in patients given postoperative radiation for subtotally resected pituitary adenomas. J Neuro Oncol 1993; 16:227–232.CrossRefGoogle Scholar
  18. 17.
    Raghavan R, Harrison D, Ince PG, James RA, Daniels M, Birch P, Caldwell GI, Kendall-Taylor P. Oncoprotein immunoreactivity in human pituitary tumours. Clin Endocrinol 1994; 40:117–126.CrossRefGoogle Scholar
  19. 18.
    Takino H, Herman V, Weiss M, Melmed S. Purine-binding factor (nm23) gene expression in pituitary tumors: marker of adenoma invasiveness. J Clin Endocrinol Metab 1995; 80:1733–1738.PubMedCrossRefGoogle Scholar
  20. 19.
    Pei L, Melmed S, Scheithauer B, Kovacs K, Benedict WF, Prager D. Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: evidence for a chromosome 13 tumor suppressor gene other than RB. Cancer Res 1995; 55:1613–1616.PubMedGoogle Scholar
  21. 20.
    Kleinschmidt-DeMasters BK, Conway D, Franklin WA, Lillehei KO, Kruse C. Neural cell adhesion molecule expression in human pituitary adenomas. J Neuro Oncol 1995; 25:205–213.CrossRefGoogle Scholar
  22. 21.
    Ezzat S, Walpola IA, Ramyar L, Smyth HS, and Asa SL. Membrane-anchored expression of transforming growth factor-alpha in human pituitary adenoma cells. J Clin Endocrinol Metab 1995; 80:534–539.PubMedCrossRefGoogle Scholar
  23. 22.
    Lange M, Pagotto U, Hopfner U, Ehrenreich H, Oeckler R, Sinowatz F, Stalla GK. Endothelin expression in normal human anterior pituitaries and pituitary adenomas. J. Clin. Endocrind. Metab. 1994; 79:1864–1870.CrossRefGoogle Scholar
  24. 23.
    Steel JH, Martinez A, Springall DR, Treston AM, Cuttitta F, Polak JM. Peptidylglycine 03B1–amidating monooxygenase (PAM) immunoreactivity and messenger RNA in human pituitary and increased expression in pituitary tumors. Cell Tissue Res 1994; 276:197–207.PubMedCrossRefGoogle Scholar
  25. 24.
    Chaidarun SS, Eggo MC, Sheppard MC, Stewart PM. Expression of epidermal growth factor (EGF), its receptor, and related oncoprotein erbB-2 in human pituitary tumors and response to EGF in vitro. Endocrinology 1994; 135:2012–2021.PubMedCrossRefGoogle Scholar
  26. 25.
    Farnoud MR, Farhadian F, Samuel JL, Derome P, Peillon F, and Li JY. Fibronectin isoforms are differentially expressed in normal and adenomatous human anterior pituitaries. Int J Cancer 1995; 61:27–34.PubMedCrossRefGoogle Scholar
  27. 26.
    Levy A, Hall L, Yeudall WA, Lightman SL. p53 gene mutations in pituitary adenomas: rare events. Clin Endocrinol 1994; 41:809–814.CrossRefGoogle Scholar
  28. 27.
    Asa SL, Puy LA, Lew AM, Sundmark VC, Elsholtz HP. Cell type-specific expression of the pituitary transcription activator Pit-1 in the human pituitary and pituitary adenomas. J Clin Endocrinol Metab 1993; 77:1275–1280.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 1997

Authors and Affiliations

  • B. K. Kleinschmidt-DeMasters

There are no affiliations available

Personalised recommendations